Tagged with Investment,

Europe Rainer Westermann offers a sobering take on Europe’s declining global status as both a source and recipient of biopharmaceutical innovation. He argues that the time for a paradigm shift in how the EU values innovation is now, calling for pricing system reform, speedier regulatory and HTA procedures, manufacturing investments, and…

China Suzhou’s bioBAY has emerged as one of China’s most dynamic biotechnology clusters, bringing together hundreds of biotech and medtech companies within an ecosystem designed to support the full innovation cycle, from early discovery to global partnerships. In this conversation, CEO Michael Yin reflects on how the park has evolved alongside…

Hong Kong Sabrina Chan, Senior Executive at HKAPI, highlights progress in Hong Kong’s biomedical ambitions, including establishing an independent regulator, expanding clinical trial capacity via the Greater Bay Area Clinical Trial Institute (GBAICTI), and leveraging 34 years of real-world health data. She underscores efforts to enhance primary healthcare, support rare disease access,…

France Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s most investable life sciences hubs. While less well-known internationally than Basel, Barcelona, London, or Paris, Lyon stands out from the…

Taiwan Biotechnology in Taiwan is no longer a future aspiration, but an industrial system deliberately built for global relevance. In this conversation, the Chairman and CEO of the Development Centre for Biotechnology explain how policy, data, manufacturing discipline, and clinical capability are being aligned to create a coherent national ecosystem. The…

France France and Denmark have a rich history of healthcare collaboration, from basic research to clinical trials, as well as major manufacturing investments. What links these two nations, and what are the threats to further collaborations in the coming years?   For a country with a population of just six million…

France France finally has a full budget for 2026, ending months of stasis, and providing a degree of certainty to industry. However, especially for pharma, continual price cuts threaten the sustainability of France as an investment destination, although the reindustrialisation incentives contained with the ‘France 2030’ plan are leading to an…

France Stéphane Legastelois has spent 35 years bridging science and business. After founding Indicia, he transitioned to healthcare investing, backing 30 early-stage companies, mainly in Lyon, and now heads up 33 Californie, a boutique investment firm which combines capital with strategic guidance, de-risking start-ups before Series A financing. As he explains,…

Argentina Has Argentina, for years one of the economic basket cases of Latin America, finally turned a corner? And is its pharma industry set for a bounce back?   Firebrand TV pundit-turned politician Javier Milei was elected President in late 2023 on a promise to slash public spending and state intervention.…

USA Ramon Parsons, Director of the Mount Sinai Tisch Cancer Center, reflects on four decades of progress in oncology – from molecular genetics to immunotherapy and cellular therapies – and the critical role of comprehensive cancer centres in translating science into care. He highlights relapse, resistance and funding constraints as key…

USA Glenn Robertelli, CEO of RI Bio, is shaping Rhode Island into a rising life sciences hub through strategic partnerships, innovative programs, and support for early-stage biotech. Despite the state’s small size, Rhode Island ranks fourth nationally in NIH funding and is a top ten leader in bioscience patents and medical…

France Denmark and France are intensifying their cooperation in life sciences at a time when resilience, innovation and industrial capacity have become strategic priorities for Europe. In this interview, Hanne Fugl Eskjær, Denmark’s Ambassador to France, reflects on how complementary strengths in research, digital health and public-private collaboration are shaping a…